India focused: IPO, special situations, Stylus Holdings

Himanshu Dugar

India focused: IPO, special situations

Stylus Holdings

Stylus Holdings is a buy-side equity research firm. We offer bottom-up investment ideas as well as provide on demand equity research and portfolio tracking. 
At Stylus, our focus is to identify market dislocations that can generate 20+% IRR with a reasonable margin of safety. As part of our research process, we do a deep dive into the fundamentals of the company, evaluate their competitive positioning and assess their valuation.
Our investment team is led by Himanshu Dugar. Himanshu is a Chartered Accountant and a CFA charter holder. He has 10+ years of active experience in the stock market with stints at CRISIL Research, a S&P Global copmany and Miras Investments, a single family office based in Dubai.

Equity Research Firm

Event-Driven

Manipal Health Enterprises Ltd / Event-Driven

Manipal Health Enterprises Ltd (1217834D IN)

<ul>
<li>Manipal Health Enterprises operates 49 hospitals with 13,037 licensed beds across 14 states, generating nearly ₹11,000 crore in revenue via aggressive acquisitions and brownfield expansion opportunities.;</li>
<li>Leading in CONGO-R specialties, Manipal boasts high ARPOB (₹66,145) and low ALOS (2.8 days), backed by lean opex, high EBITDA per employee, and strong institutional governance.</li>
<li>Priced at ₹560–590 (FY26 EV/EBITDA 30.5x), the IPO offers limited listing gains. Long-term upside hinges on brownfield bed operationalization, doctor retention, and navigating Metro overcapacity.</li>
</ul>


Manipal Health Enterprises operates 49 hospitals with 13,037 licensed beds across 14 states, generating nearly ₹11,000 crore in revenue via aggressive acquisitions and brownfield expansion opportunities.;
Leading in CONGO-R specialties, Manipal boasts high ARPOB (₹66,145) and low ALOS (2.8 days), backed by lean opex, high EBITDA per employee, and strong institutional governance.
Priced at ₹560–590 (FY26 EV/EBITDA 30.5x), the IPO offers limited listing gains. Long-term upside hinges on brownfield bed operationalization, doctor retention, and navigating Metro overcapacity.


Manipal Health IPO: Skip the Listing, Buy the Dips?

External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Thematic (Sector/Industry)

<ul><li>We expect companies under our Pharma coverage to report high singledigit growth (6.2% YoY), primarily driven by Injectable and Generic segment.</li><li>With elevated prices of organic chemicals and solvents led by the Russia-Ukraine conflict, persistently high API/KSM costs from China that have risen ~7-8% QoQ in Q4FY22</li><li>OUR TOP POSITIVE PLAYS ARE: Cipla, Abbott India, KIMS, HCG</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

We expect companies under our Pharma coverage to report high singledigit growth (6.2% YoY), primarily driven by Injectable and Generic segment.With elevated prices of organic chemicals and solvents led by the Russia-Ukraine conflict, persistently high API/KSM costs from China that have risen ~7-8% QoQ in Q4FY22OUR TOP POSITIVE PLAYS ARE: Cipla, Abbott India, KIMS, HCGContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pharma Q4FY22 Preview: Cost Pressure and Pricing Erosion Compress Margins

Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>Yatharth is an NCR-anchored quaternary hospital chain compounding revenue at 40% CAGR, the fastest in India's listed hospital universe.</li>
<li>From a current 2,550 beds, Yatharth targets 5,000 beds by FY29, deploying Rs. 1,500 crore capex over the next 4-5 years across NCR and North India.</li>
<li>Trading at a 38-60% discount to large-cap peers purely on ramp-up drag and high government receivables, both of which are structurally reversing over the next 12-18 months.</li>
</ul>


Yatharth is an NCR-anchored quaternary hospital chain compounding revenue at 40% CAGR, the fastest in India's listed hospital universe.
From a current 2,550 beds, Yatharth targets 5,000 beds by FY29, deploying Rs. 1,500 crore capex over the next 4-5 years across NCR and North India.
Trading at a 38-60% discount to large-cap peers purely on ramp-up drag and high government receivables, both of which are structurally reversing over the next 12-18 months.


Yatharth Hospital: The Small-Cap Riding India's Hospital Capex Supercycle

India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Apollo Hospitals Enterprise / Equity Bottom-Up

<ul>
<li>India's medical tourism sector faces a simultaneous shock: a 50–75% crash in West Asian patient volumes due to the Iran-Israel-US conflict.</li>
<li>West Asia and Bangladesh together account for roughly 60%+ of India's inbound medical travelers. The dual disruption threatens near-term revenues at Fortis, Apollo, and KIMSHEALTH.</li>
<li>India's structural advantages in cost and clinical depth remain intact, but concentration risk in source markets is no longer theoretical. </li>
</ul>


India's medical tourism sector faces a simultaneous shock: a 50–75% crash in West Asian patient volumes due to the Iran-Israel-US conflict.
West Asia and Bangladesh together account for roughly 60%+ of India's inbound medical travelers. The dual disruption threatens near-term revenues at Fortis, Apollo, and KIMSHEALTH.
India's structural advantages in cost and clinical depth remain intact, but concentration risk in source markets is no longer theoretical. 


India Loses Patients: The Geopolitical Stress Test for India's Medical Tourism Sector

Global Healthcare Analyst

Tina Banerjee

Equity Capital Markets

<ul>
<li>Park Medi World has filed for IPO to raise up to INR 9,200M. The company plans to sell 56.8M shares at between INR 154 and INR 162 per share.</li>
<li>Park Medi World is the second largest private hospital chain in North India with a capacity of 3,000 beds, and the largest private hospital chain in Haryana.</li>
<li>Valuation reasonable considering the fact that it lags behind on many fronts compared to its peers. Bullish on Indian hospital players, but we think investors can comfortably skip this issue.</li>
</ul>


Park Medi World has filed for IPO to raise up to INR 9,200M. The company plans to sell 56.8M shares at between INR 154 and INR 162 per share.
Park Medi World is the second largest private hospital chain in North India with a capacity of 3,000 beds, and the largest private hospital chain in Haryana.
Valuation reasonable considering the fact that it lags behind on many fronts compared to its peers. Bullish on Indian hospital players, but we think investors can comfortably skip this issue.


Park Medi World IPO: Ability To Maintain Margin Dicey, Avoid Parking Funds In This Issue

India

Krishna Institute of Medical Sciences (KIMS) is an Indian multi-speciality hospital chain that offers a comprehensive range of healthcare services across various medical and surgical specialties, including cardiac sciences, oncology, neurosciences, orthopaedics, and organ transplantation. KIMS operates a network of hospitals providing multidisciplinary integrated tertiary and quaternary healthcare. The company is headquartered in Secunderabad, India, and was founded in 2000.

Krishna Institute of Medical Sciences (KIMS IN)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Krishna Institute of Medical Sciences (KIMS IN)

Manipal Health IPO: Skip the Listing, Buy the Dips?

Manipal Health Enterprises is a leading hospital operator with strong financials and growth potential, but the IPO may not offer immediate gains...

Himanshu Dugar

Pharma Q4FY22 Preview: Cost Pressure and Pricing Erosion Compress Margins

We expect companies under our Pharma coverage to report high singledigit growth (6.2% YoY), primarily driven by Injectable and Generic segment.

Axis Direct

Yatharth Hospital: The Small-Cap Riding India's Hospital Capex Supercycle

Yatharth, a fast-growing hospital chain in NCR, aims to double its bed capacity by FY29 with significant capex, poised for growth despite current...

Nimish Maheshwari

India Loses Patients: The Geopolitical Stress Test for India's Medical Tourism Sector

India's medical tourism sector is facing a significant decline in patient volumes from West Asia due to the Iran-Israel-US conflict, impacting...

Sudarshan Bhandari

Park Medi World IPO: Ability To Maintain Margin Dicey, Avoid Parking Funds In This Issue

Park Medi World launched IPO to raise INR 9.2B. Valuation reasonable but lags behind peers. Geographic, payor and specialties concentration are...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Manipal Health IPO: Skip the Listing, Buy the Dips?

​Manipal Health Enterprises is a leading hospital operator with strong financials and growth potential, but the IPO may not offer immediate gains...

Himanshu Dugar

Pharma Q4FY22 Preview: Cost Pressure and Pricing Erosion Compress Margins

We expect companies under our Pharma coverage to report high singledigit growth (6.2% YoY), primarily driven by Injectable and Generic segment.

Axis Direct

Yatharth Hospital: The Small-Cap Riding India's Hospital Capex Supercycle

​Yatharth, a fast-growing hospital chain in NCR, aims to double its bed capacity by FY29 with significant capex, poised for growth despite current...

Nimish Maheshwari

India Loses Patients: The Geopolitical Stress Test for India's Medical Tourism Sector

​India's medical tourism sector is facing a significant decline in patient volumes from West Asia due to the Iran-Israel-US conflict, impacting...

Sudarshan Bhandari

Park Medi World IPO: Ability To Maintain Margin Dicey, Avoid Parking Funds In This Issue

​Park Medi World launched IPO to raise INR 9.2B. Valuation reasonable but lags behind peers. Geographic, payor and specialties concentration are...

Tina Banerjee

Manipal Health Enterprises is a leading hospital operator with strong financials and growth potential, but the IPO may not offer immediate gains...

Yatharth, a fast-growing hospital chain in NCR, aims to double its bed capacity by FY29 with significant capex, poised for growth despite current...

India's medical tourism sector is facing a significant decline in patient volumes from West Asia due to the Iran-Israel-US conflict, impacting...

Park Medi World launched IPO to raise INR 9.2B. Valuation reasonable but lags behind peers. Geographic, payor and specialties concentration are...